发明名称 Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
摘要 <p>A process for the long term modification and regulation of lipid metabolism -- generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes) -- by administratlon (i.e., by feed or injection into the bloodstream) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.</p>
申请公布号 EP0917874(B1) 申请公布日期 2008.04.09
申请号 EP19980110831 申请日期 1991.01.07
申请人 LOUISIANA STATE UNIVERSITY AGRICULTURAL AND MECHANICAL COLLEGE 发明人 CINCOTTA, ANTHONY;MEIER, ALBERT
分类号 A61K31/48;A61K31/00;A61K31/13;A61K31/15;A61K31/166;A61K31/195;A61K31/221;A61K31/35;A61K31/352;A61K31/40;A61K31/405;A61K31/435;A61K31/439;A61K31/445;A61K31/4515;A61K31/454;A61K31/46;A61K31/475;A61K31/496;A61K31/54;A61K31/5415;A61K31/55;A61K31/551;A61K31/5513;A61K31/695;A61K38/22;A61K45/00;A61K45/06;A61P3/08;A61P3/10;C07D457/00;C07D457/04;G01N33/74 主分类号 A61K31/48
代理机构 代理人
主权项
地址